Загрузка...
Emerging serine-threonine kinase inhibitors for treating ovarian cancer
INTRODUCTION: Ovarian cancer is the leading cause of gynecologic cancer death, owing to high rates of incurable, recurrent disease after initial treatment. Serine threonine kinases (STKs) have been proposed as potential therapeutic targets in ovarian cancer because of their role in the initiation an...
Сохранить в:
| Опубликовано в: : | Expert Opin Emerg Drugs |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7526049/ https://ncbi.nlm.nih.gov/pubmed/31755325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728214.2019.1696773 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|